ASCO GU 2021

Results from Phase 3 CLEAR Study for Advanced RRC

In patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we...

Read More

ASCO GU 2021 Kicks Off! What to Expect

The 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and...

Read More

PhysQuiz Answers! ASCO GU: Renal Cell Carcinoma

1)  Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC:   a) pembrolizumab or...

Read More
  • 1
  • 2

For latest news and updates
Email-id is invalid